In most workplaces, the capable become the crowded. Success attracts requests. Before long, your calendar looks like a traffic jam of “quick...
Why Saying No Is One of the Most Strategic Career Moves
read more
INSIGHTS ON PHARMA INNOVATION, ETHICS, AND LEADERSHIP
Explore thought leadership articles and stories shaping the future.
Latest Insights
The Future of Payer–Regulator Collaboration
For decades, regulators and payers have operated in parallel worlds. Regulators judged safety and efficacy. Payers judged value and affordability....
The Economics of Prevention and the Future of Value-Based Healthcare
Healthcare systems face huge pressure from aging, chronic illness, and high costs. Yet much of the industry’s innovation still targets treatment...
Aligning Corporate Purpose with Global Access Policy
Corporate purpose statements are everywhere — printed on annual reports, displayed in office lobbies, and recited at town halls. “We transform...
Rethinking Health Technology Assessment in the Era of Personalised Medicine
When health technology assessment (HTA) systems were created, they were designed for a different era. The model assumed large, randomised trials,...
How to Lead Market Access Teams in the New Innovation Economy
When I first managed a market access team, I thought leadership meant having the answers. It didn’t take long to learn that it meant asking the...
Designing Evidence Strategies for Early Value Recognition
In one market access workshop, a payer representative once said to a biotech team, “Your data are excellent. They just don’t answer any of our...
Patient Partnerships as Strategic Assets
When I joined a cross-functional launch team for a rare oncology therapy, I remember a patient advocate standing up in the room and saying, “You...
The Future of Global Market Access in an AI-Driven World
Artificial intelligence has entered every corner of pharmaceutical development — discovery, clinical design, safety, and supply chain. Yet its most...
Building Trust with Regulators Through Early Engagement
The phrase “regulatory strategy” often conjures images of submission deadlines, data packages, and procedural checklists. Yet the most effective...
Pricing Innovation in the Age of Public Scrutiny
A few years ago, a journalist asked a question at a press briefing that silenced the room: “If this drug saves lives, why does it cost more than a...
Launching an Innovative Drug When the Beneficiaries Are in Low- and Middle-Income Countries
In boardrooms across Europe and the United States, I have often heard a version of the same question: “How do we make this viable when most patients...
Building a Rare Disease Portfolio Strategy That Lasts
A decade ago, rare disease development was seen as niche science with limited commercial logic. Today, it sits at the heart of biopharma innovation....